ACTR-93. A PHASE I STUDY OF MLN0128 (TAK-228) AND BEVACIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING GLIOBLASTOMA

BACKGROUND: The P13K/Akt/mTOR signaling axis plays a central role in cell growth and survival in a variety of cancers. MLN0128(TAK-228) is an oral inhibitor of TORC1/2 complexes. Bevacizumab is a monoclonal antibody targeting VEGF with activity in some cancers. METHODS: We conducted a Cancer Therape...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Nayak, Lakshmi, Hays, John, Do, Khanh, Muzikansky, Alona, Gaffey, Sarah, Lee, Eudocia, Rinne, Mikael, Norden, Andrew, Beroukhim, Rameen, Puduvalli, Vinay, Wen, Patrick, Doyle, L Austin, Chen, Helen, Shapiro, Geoffrey, Reardon, David
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692652/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.077
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi